MG
CORT icon

Michael Gelband’s Corcept Therapeutics CORT Stock Holding History

Michael Gelband’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-106,147
Closed -$4.28M – 1641
2026
Q1 		$4.28M Buy
+106,147
New +$3.97M 0.03% 490
2023
Q4 		– Sell
-24,832
Closed -$677K – 1552
2023
Q3 		$677K Sell
24,832
-80,278
-76% -$2.32M 0.01% 1129
2023
Q2 		$2.34M Buy
105,110
+48,701
+86% +$1.12M 0.02% 747
2023
Q1 		$1.22M Buy
56,409
+14,755
+35% +$323K 0.01% 1072
2022
Q4 		$846K Buy
+41,654
New +$1.04M 0.01% 1006
2022
Q3 		– Sell
-19,210
Closed -$457K – 1933
2022
Q2 		$457K Sell
19,210
-68,544
-78% -$1.49M 0.01% 1400
2022
Q1 		$1.98M Buy
87,754
+10,727
+14% +$228K 0.03% 787
2021
Q4 		$1.52M Buy
+77,027
New +$1.56M 0.02% 870
2021
Q1 		– Sell
-16,053
Closed -$420K – 2170
2020
Q4 		$420K Sell
16,053
-27,537
-63% -$580K ﹤0.01% 1352
2020
Q3 		$759K Buy
+43,590
New +$695K 0.02% 800
2020
Q1 		– Sell
-37,139
Closed -$449K – 1153
2019
Q4 		$449K Buy
37,139
+15,074
+68% +$210K 0.01% 921
2019
Q3 		$312K Buy
+22,065
New +$271K 0.01% 856

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's CORT Position: Q2 2026 in Review

Michael Gelband sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 106,147 shares — an estimated $4.28M sold.

Michael Gelband first reported a position in CORT in Q3 2019 and held it in 12 quarters. The position peaked at $4.28M in Q1 2026. 420 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Michael Gelband reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 106,147 Corcept Therapeutics shares in Q2 2026, an estimated $4.28M.
  • Michael Gelband first reported a position in Corcept Therapeutics in Q3 2019 and held it in 12 quarters.
  • Michael Gelband's Corcept Therapeutics position peaked at $4.28M in Q1 2026.
  • 420 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.